Core Viewpoint - The article discusses a groundbreaking study on a novel gene editing technique for treating congenital ichthyosis, a rare genetic skin disorder, using lipid nanoparticles for safe and effective in situ editing of disease-causing mutations [3][5][7]. Group 1: Research Findings - The study published in *Cell Stem Cell* on January 27, 2026, presents a non-viral gene editing method targeting the most common mutation causing autosomal recessive congenital ichthyosis (ARCI), specifically TGM1 c.877-2A>G, which leads to abnormal splicing of the TGM1 gene [3][5]. - The research demonstrated that local application of lipid nanoparticles (LNP) delivered a cytosine base editor, achieving approximately 12% repair of the wild-type TGM1 gene and restoring about 30% of wild-type TGM1 enzyme activity [5]. - Toxicity studies and comprehensive off-target analyses indicated that the therapy exhibited excellent safety characteristics, even with repeated applications, and high-sensitivity methods confirmed that LNPs or their delivered payloads did not show systemic distribution [5][7]. Group 2: Implications for Future Therapies - The study provides comprehensive preclinical data on the feasibility of in situ repair of genetic mutations causing hereditary skin diseases, showcasing its therapeutic potential and paving the way for next-generation curative therapies for severe genetic skin disorders [7].